FNDC5 and cancer: This would enable assessment of additive value, evaluation of dose–response relationships between irisin levels and clinical outcomes, and exploration of interventional studies targeting irisin pathways through exercise, metabolic modulation, or pharmacological agents in cancers where irisin demonstrates functional relevance.